NAYA BIOSCIENCES INC. - COMMON STOCK

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering 

13 Jan 2025 09:15:44 By Nasdaq GlobeNewswire

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

06 Jan 2025 08:30:00 By Nasdaq GlobeNewswire

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

31 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

24 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

21 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

14 Oct 2024 09:18:20 By Nasdaq GlobeNewswire

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

14 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

INVO Reports Record First Quarter 2024 Financial Results

15 May 2024 16:15:00 By Nasdaq GlobeNewswire

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

16 Apr 2024 16:59:29 By Nasdaq GlobeNewswire